AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development progress of its vaccine candidates. The company has submitted a preliminary market filing for its 13-valent pneumococcal conjugate vaccine, designed to prevent invasive diseases caused by 13 pneumococcal serotypes, including bacteremic pneumonia, meningitis, sepsis, and bacteremia, in infants and children from 6 weeks to 5 years old. Pneumonia is a leading cause of illness and mortality among children under 5, and the World Health Organization has identified childhood pneumonia as a high-priority disease for vaccine prevention, endorsing the use of the 13-valent pneumococcal conjugate vaccine.
Additionally, the Chinese pharmaceutical company announced the initiation of a Phase II study for its tetravalent conjugate meningococcal vaccine in Yunnan province. This study is a randomized, blinded, and parallel-controlled trial.
AIM, recognized as the world’s second-largest provider of rabies vaccines, reported the completion of on-site work in a Phase III clinical trial for its serum-free iterative rabies vaccine, with plans to finalize market filing within the year. The company also submitted a preliminary clinical trial filing for its innovative human diploid rabies vaccine, expected in the first half of 2024. Furthermore, AIM has initiated a market approval review for its mRNA-based rabies vaccine, which is noted as the first non-COVID mRNA vaccine to reach the review stage in China.
The serum-free iterative rabies vaccine is an upgraded product that does not contain animal serum, setting it apart from existing Vero cell and human diploid rabies vaccines. To date, no similar product has been approved globally.- Flcube.com
